Mechanisms of norcantharidin against renal tubulointerstitial fibrosis

Abstract

Renal tubulointerstitial fibrosis (RTIF) is a common feature and inevitable consequence of all progressive chronic kidney diseases, leading to end-stage renal failure regardless of the initial cause. Although research over the past few decades has greatly improved our understanding of the pathophysiology of RTIF, until now there has been no specific treatment available that can halt the progression of RTIF. Norcantharidin (NCTD) is a demethylated analogue of cantharidin, a natural compound isolated from 1500 species of medicinal insect, the blister beetle (Mylabris phalerata Pallas), traditionally used for medicinal purposes. Many studies have found that NCTD can attenuate RTIF and has the potential to be an anti-RTIF drug. This article reviews the recent progress of NCTD in the treatment of RTIF, with emphasis on the pharmacological mechanism of NCTD against RTIF.

Keywords: Long non-coding RNAs (lncRNAs); Norcantharidin (NCTD); Nuclear factor-κB (NF-κB); Protein phosphatase 2A (PP2A); Renal tubulointerstitial fibrosis (RTIF); Transforming growth factor-β1 (TGF-β1); Tumor necrosis factor-like weak inducer of apoptosis (TWEAK).